Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lowered its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 20.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 290,353 shares of the company’s stock after selling 72,595 shares during the period. Pacer Advisors Inc. owned 0.50% of Harmony Biosciences worth $10,865,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC boosted its stake in Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the period. Leonteq Securities AG bought a new position in Harmony Biosciences in the 4th quarter worth about $30,000. Allworth Financial LP grew its position in Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the last quarter. Clearstead Advisors LLC increased its stake in shares of Harmony Biosciences by 145.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after purchasing an additional 699 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Harmony Biosciences in the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY opened at $33.28 on Monday. The company has a 50 day moving average of $31.44 and a 200-day moving average of $33.06. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.93 billion, a P/E ratio of 13.42, a P/E/G ratio of 0.23 and a beta of 0.96. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. During the same quarter in the prior year, the business earned $0.78 EPS. Harmony Biosciences’s revenue was up 16.6% compared to the same quarter last year. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a research report on Monday, February 23rd. Weiss Ratings cut Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. HC Wainwright reaffirmed a “buy” rating on shares of Harmony Biosciences in a research note on Friday, May 22nd. Needham & Company LLC cut their target price on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Finally, UBS Group reduced their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $40.89.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.